JP2004535795A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004535795A5 JP2004535795A5 JP2002589630A JP2002589630A JP2004535795A5 JP 2004535795 A5 JP2004535795 A5 JP 2004535795A5 JP 2002589630 A JP2002589630 A JP 2002589630A JP 2002589630 A JP2002589630 A JP 2002589630A JP 2004535795 A5 JP2004535795 A5 JP 2004535795A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- amino acid
- nucleic acid
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 102000004127 Cytokines Human genes 0.000 claims 9
- 108090000695 Cytokines Proteins 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 230000027455 binding Effects 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000004890 epithelial barrier function Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000004347 intestinal mucosa Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29023901P | 2001-05-10 | 2001-05-10 | |
| PCT/US2002/014587 WO2002092762A2 (en) | 2001-05-10 | 2002-05-08 | Cytokine polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004535795A JP2004535795A (ja) | 2004-12-02 |
| JP2004535795A5 true JP2004535795A5 (cg-RX-API-DMAC7.html) | 2005-12-22 |
Family
ID=23115104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002589630A Withdrawn JP2004535795A (ja) | 2001-05-10 | 2002-05-08 | サイトカインポリペプチド群 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20030104579A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1412499A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004535795A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002314774B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2446180A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA03010181A (cg-RX-API-DMAC7.html) |
| PL (1) | PL373008A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002092762A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1717316T3 (da) | 2000-06-30 | 2008-12-08 | Zymogenetics Inc | Allelisk variant af interferon-lignende protein Zcyto21 |
| US7038032B2 (en) | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| US7910313B2 (en) | 2001-04-20 | 2011-03-22 | Zymogenetics, Inc. | Cytokine protein family |
| DE60237791D1 (de) * | 2001-04-20 | 2010-11-04 | Bristol Myers Squibb Co | Zytokinproteinfamilie |
| AU2003215136A1 (en) | 2002-02-08 | 2003-09-02 | University Of Medicine And Dentistry Of New Jersey | Ifn-a/b-independent mechanism of antiviral protection |
| US7135170B2 (en) | 2002-10-23 | 2006-11-14 | Zymogenetics, Inc. | Methods for treating viral infection using IL-28 and IL-29 |
| PT2251353E (pt) | 2003-08-07 | 2013-05-07 | Zymogenetics Inc | Preparações homogéneas de il-28 e il-29 |
| CA2558829C (en) | 2004-04-02 | 2014-03-11 | Zymogenetics, Inc. | Methods for treating viral infection using il-28 and il-29 cysteine mutants |
| CA2574564C (en) | 2004-07-29 | 2013-04-16 | Zymogenetics, Inc. | Use of il-28 and il-29 to treat cancer and autoimmune disorders |
| US8158129B2 (en) * | 2005-04-06 | 2012-04-17 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo |
| US20070020227A1 (en) * | 2005-07-20 | 2007-01-25 | Sheppard Paul O | Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders |
| EP2922870B1 (en) * | 2012-11-21 | 2019-08-07 | The Governors of the University of Alberta | Immunomodulatory peptides and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1717316T3 (da) * | 2000-06-30 | 2008-12-08 | Zymogenetics Inc | Allelisk variant af interferon-lignende protein Zcyto21 |
| AU2001271589A1 (en) * | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Mammalian secreted proteins |
-
2002
- 2002-05-08 AU AU2002314774A patent/AU2002314774B2/en not_active Ceased
- 2002-05-08 PL PL02373008A patent/PL373008A1/xx not_active Application Discontinuation
- 2002-05-08 WO PCT/US2002/014587 patent/WO2002092762A2/en not_active Ceased
- 2002-05-08 EP EP02741697A patent/EP1412499A4/en not_active Withdrawn
- 2002-05-08 US US10/142,717 patent/US20030104579A1/en not_active Abandoned
- 2002-05-08 MX MXPA03010181A patent/MXPA03010181A/es unknown
- 2002-05-08 JP JP2002589630A patent/JP2004535795A/ja not_active Withdrawn
- 2002-05-08 CA CA002446180A patent/CA2446180A1/en not_active Abandoned
-
2006
- 2006-11-20 US US11/602,056 patent/US20070081973A1/en not_active Abandoned